Clinical Trials
40 trialsNCT05579366 2026-05-26
RAINFOL-01
Genmab
Phase 1/2 Recruiting
NCT07044336 2026-05-20
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
AstraZeneca
Phase 3 Recruiting
NCT06989112 2026-05-06
DE-01
AstraZeneca
Phase 3 Recruiting
NCT07542704 2026-04-21
A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies
Kumquat Biosciences Inc.
Phase 1 Not yet recruiting
NCT06952660 2026-04-20
Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer
Pfizer
Phase 4 Recruiting
NCT03555422 2026-04-13
ENGOT-EN5
Karyopharm Therapeutics Inc
Phase 3 Completed
NCT07038369 2026-03-17
A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
Atavistik Bio, Inc
Phase 1 Active not recruiting
NCT06815939 2026-01-29
OPTICS
DL Analytics
Phase NA Recruiting
NCT04579380 2025-12-19
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
Seagen Inc.
Phase 2 Active not recruiting
NCT04106492 2025-11-14
Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors
Shasqi, Inc.
Phase 1/2 Terminated
NCT05864144 2025-08-15
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Sensei Biotherapeutics, Inc.
Phase 1/2 Active not recruiting
NCT05949632 2025-08-03
A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors
Incyte Corporation
Phase 1/2 Terminated
NCT03395080 2025-08-01
P204
Leap Therapeutics, Inc.
Phase 2 Completed
NCT03476681 2025-04-24
Study of NEO-201 in Solid Tumors Expansion Cohorts
Precision Biologics, Inc
Phase 1/2 Recruiting
NCT04774952 2025-04-15
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
Revolution Medicines, Inc.
Phase 1 Completed
NCT04383210 2025-04-03
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
Elevation Oncology
Phase 2 Terminated
NCT06692166 2024-11-22
A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 3 Recruiting
NCT02164461 2024-05-20
Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer
Advaxis, Inc.
Phase 1 Completed
NCT04424641 2023-07-25
A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors
Genmab
Phase 1/2 Terminated
NCT05708950 2023-07-13
A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
Kineta Inc.
Phase 1/2 Unknown
NCT03989115 2023-06-26
Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC
Revolution Medicines, Inc.
Phase 1/2 Completed
NCT03073525 2023-04-05
A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers
Gradalis, Inc.
Phase 2 Completed
NCT03634982 2022-09-01
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
Revolution Medicines, Inc.
Phase 1 Unknown
NCT02209532 2019-03-25
FILM
Novadaq Technologies ULC, now a part of Stryker
Phase NA Completed
NCT01420081 2019-01-08
A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer
Pfizer
Phase 2 Terminated
NCT00471120 2015-08-05
Feasibility Study: Accuracy of Biomarker in Detection of Endometrial Cancer
CytoCore, Inc.
Phase NA Terminated
NCT01379534 2015-05-20
A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
Novartis
Phase 2 Completed
NCT01234012 2015-03-10
Study of IMF-001 in Patients With Malignancies Expressing NY-ESO-1
ImmunoFrontier, Inc.
Phase 1 Completed
NCT01969396 2014-12-23
Evaluation of the Goldstein SonoBiopsyâ„¢ Catheter for Diagnosing Endometrial Pathology
Cook Group Incorporated
Phase NA Terminated
NCT00050440 2013-01-08
Phase 2 Study of ET-743 (Trabectedin) in Patients With Persistent or Recurrent Endometrial Carcinoma
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Completed
NCT01045187 2012-08-01
Feasibility Study Using the Xoft System for the Treatment of Endometrial Cancer
Xoft, Inc.
Phase NA Completed
NCT00628901 2012-07-11
A Prospective Study Comparing Contour SE™ Microspheres to Embosphere® Microspheres for Treating Symptomatic Uterine Fibroids With Uterine Fibroid Embolization (UFE)
Boston Scientific Corporation
Phase 4 Completed
NCT01290406 2012-06-21
BEZ235 Trial in Patients With Advanced Endometrial Carcinoma
Novartis
Phase 2 Withdrawn
NCT00513851 2011-09-27
Phase 1 Study of OSI-930 in Cancer Patients
Astellas Pharma Inc
Phase 1 Completed
NCT00776074 2010-06-22
A Pharmacodynamic Study of Leuprorelin Gelatin-Free Formulation in Female Subjects With Uterine Fibroids.
Takeda
Phase 2 Completed
NCT00190983 2009-11-20
A Trial for Patients With Advanced/Recurrent Cervical Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00377520 2009-11-20
A Trial for Patients With Advanced/Recurrent Endometrial Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00782041 2009-09-15
Patients Who Have Failed First Line Treatment for Locally Advanced and/or Metastatic Cervical Cancer
Sanofi
Phase 2 Terminated
NCT00121030 2007-12-24
Treatment for Patients With Gynecological Malignancies Who Suffer From Anemia Due to Chemotherapy
Amgen
Phase 2 Completed
NCT00190918 2007-08-09
A Trial for Patients With Gestational Trophoblastic Disease
Eli Lilly and Company
Phase 2 Completed